Podcasts about Genomics

In this episode of Ageless Future, Regan Archibald sits down with Dr. Aaron Hartman, a leading integrative and functional medicine physician from Richmond, Virginia, to explore how personal struggle reshaped his medical philosophy. Dr. Hartman shares the remarkable story of his adopted daughter, Anna, who was born with severe neurological challenges after prenatal drug exposure and was given little hope by conventional medicine. Refusing invasive interventions, Dr. Hartman and his wife instead pioneered a personalized, root-cause approach—combining nutrition, genomic testing, hyperbaric therapy, peptides, and stem cells—to help Anna achieve milestones doctors said were impossible. Their journey reveals both the shortcomings of standard medical systems and the transformative power of curiosity, persistence, and faith. The conversation expands to the healing of mothers, trauma recovery, and how functional medicine empowers both patients and practitioners to think, innovate, and restore true health. LIKE/FOLLOW/SUBSCRIBE DR. HARTMAN:Website: https://uncurablebook.com/YouTube: https://www.youtube.com/c/AaronHartmanMDInstagram: https://www.instagram.com/rvaintegrative/Facebook: https://www.facebook.com/RVAintegrativeLIKE/FOLLOW/SUBSCRIBE AGELESS FUTURE:YouTube: https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureInstagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/

EPISODE DESCRIPTIONRebecca V. Nellis never meant to run a nonprofit. She just never left. Twenty years later, she's still helming Cancer and Careers after a Craigslist maternity-leave temp job turned into a lifelong mission.In this 60-minute doubleheader, we cover everything from theater nerdom and improv rules for surviving bureaucracy, to hanging up on Jon Bon Jovi, to navigating cancer while working—or working while surviving cancer. Same thing.Rebecca's path is part Second City, part Prague hostel, part Upper East Side grant writer, and somehow all of that makes perfect sense. She breaks down how theater kids become nonprofit lifers, how “sample sale feminism” helped shape a cancer rights org, and how you know when the work is finally worth staying for.Also: Cleavon Little. Tap Dance Kid. 42 countries. And one extremely awkward moment involving a room full of women's handbags and one very confused Matthew.If you've ever had to hide your diagnosis to keep a job—or wanted to burn the whole HR system down—this one's for you.RELATED LINKSCancer and CareersRebecca Nellis on LinkedIn2024 Cancer and Careers Research ReportWorking with Cancer Pledge (Publicis)CEW FoundationI'm Not Rappaport – Broadway InfoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship opportunities, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

It's The Ranch It Up Radio Show! Join Jeff Tigger Erhardt, Rebecca Wanner AKA BEC and their crew as they hear the latest reactions to potential imports of Argentine Beef.  Plus, part 2 of genomically testing the cow herd and when it comes to nutrition, don't forget about the bulls.  Plus, market reports, upcoming sales and lots more on this all-new episode of The Ranch It Up Radio Show.  Be sure to subscribe on your favorite podcasting app or on the Ranch It Up Radio Show YouTube Channel. Season 5, EPISODE 260 Cattle & Producer Groups React To Potential Imports of Argentine Beef   Last Sunday President Donald Trump said the United States could purchase Argentinian beef in an attempt to bring down prices for American consumers.  This sparked immediate reaction from our cattle associations and organizations. Reference: https://apnews.com/article/beef-argentina-us-consumers-prices-f7fadbe1b3fef4646f9c3623f901209a National Cattlemen's Beef Association (NCBA) Reaction To Argentine Beef NCBA's family farmers and ranchers have numerous concerns with importing more Argentinian beef to lower prices for consumers. This plan only creates chaos at a critical time of the year for American cattle producers, while doing nothing to lower grocery store prices," said NCBA CEO Colin Woodall. "Additionally, Argentina has a deeply unbalanced trade relationship with the U.S. In the past five years Argentina has sold more than $801 million of beef into the U.S. market. By comparison, the U.S. has sold just over $7 million worth of American beef to Argentina. Argentina also has a history of foot-and-mouth disease, which if brought to the United States, could decimate our domestic livestock production. REFERENCE: https://www.nationalbeefwire.com/ncba-argentinian-beef-import-plan-harms-u-s-cattle-producers United States Cattlemen's Association (USCA) Reaction To Argentine Beef The current price of beef on grocery store shelves reflects the true, inflation-adjusted cost of raising cattle in America today.  Already this year, the U.S. has imported more than 1.26 million metric tons of beef, primarily from Australia, Canada, Brazil, Mexico, and New Zealand. Increasing imports under current rules ultimately benefits foreign suppliers and multinational packers, while putting U.S. ranchers on the losing end and depriving American consumers of honest transparency at the meat counter. REFERENCE: https://www.nationalbeefwire.com/usca-comments-on-president-trump-s-remarks-regarding-beef-prices-and-proposed-imports-from-argentina R-Calf USA Reaction To Argentine Beef Global packers are importing beef from about 20 different countries, including Argentina, and because we do not have a mandatory country-of-origin labeling law for beef, the global packers do not need to reduce the price of imported product compared to domestic product. This negates any theoretical benefit of using more imports to drive down domestic beef prices. We urge the president to manage imports, restore mandatory country-of-origin labeling for beef, and put an end to the monopolistic control that packers and retailers have over our beef supply chain. Doing so will incentivize America's ranchers to rebuild and expand the U.S. herd to meet our national security needs and ensure that consumer beef prices are determined by competitive market forces. REFERENCE: https://www.nationalbeefwire.com/statement-on-plan-to-increase-argentine-beef-imports Fall Bull Nutrition From Westway Feed Products Nutritional balance is a cornerstone of herd health and productivity. According to Dr. Kelly Sanders of Westway Feed Products, deficiencies often go unnoticed until performance suffers. Signs Of Nutritional Deficiencies In Cattle Poor Body Condition: Thin cows, visible ribs, or weak muscling. Reduced Fertility: Open cows, delayed cycling, or poor conception rates. Coat and Hoof Issues: Rough hair coats, brittle hooves, or slow shedding. Growth Challenges in Calves: Reduced weight gains or uneven growth patterns. How To Correct Deficiencies Forage Testing: Identify nutrient gaps in hay and pasture. Targeted Supplementation: Provide liquid or block supplements to balance protein, energy, and minerals. Management Adjustments: Ensure adequate feed availability during high-demand stages such as lactation and breeding. Dr. Sanders emphasizes that proactive nutrition not only boosts herd performance but also maximizes returns on investment in genetics. Ideal Beef Genetics:  The Power Of Genomics In The Cow Herd   The Science of Selection With GEPDs from the Ideal Beef Evaluation, selecting replacement females becomes a science, not an art. Using 15 different traits, and custom indexes that combine and simplify them, phenotype and pedigree are no longer the only tools at your disposal to guide the future of your herd. Prove Your Pedigree Genotyping your herd with IBG allows parentage verification so you know where your herd comes from. All Herd and AI sires available from Jorgensen Land and Cattle are genotyped and available for sire match, and all of your genotyped females will match with their progeny. The Power of Genomic Analytics Visualize Your Results Enrolling your cattle in the IBG service gives you access to AgBoost, a revolutionary technology that turns confusing genomic results into easy to understand visualizations. This allows you to cut through the clutter and focus on your herd's future. Matings Made Easy Females enrolled in IBG are eligible for breeding suggestions powered by industry leading analytics. You pick your desired breeding outcomes, and your females will be analyzed next to Jorgensen Land and Cattles 5000+ Herd and AI sire battery, ensuring the bulls you turn out are the best for your herd's future. Enroll Cow Herd In Genomic Testing With Jorgensen Land & Cattle Gather Tissue Samples:  TSU's and Collectors are available at no charge upon request Send Samples & Data:  We handle ordering test, shipping samples & delivery of results Review Your Results: Evaluation results are loaded into your AgBoost Profile, so you are sure to have the most up to date & accurate GEPD's at your disposal Select Your Females: Use your herd's genomics to pick the best females to keep Select Your Bulls: We work with you to determine the breeding outcomes best for your herd and pick bulls that best meet those needs Featured Experts in the Cattle Industry Dr. Kelly Sanders – Westway Feed Products https://westwayfeed.com/ Follow on Facebook: @WestwayFeed Larry Gran – Jorgensen Land & Cattle https://jorgensenfarms.com/ Follow on Facebook: @JorLandCat Mark Vanzee – Livestock, Equine, & Auction Time Expert https://www.auctiontime.com/ https://www.livestockmarket.com/ https://www.equinemarket.com/ Follow on Facebook: @LivestockMkt | @EquineMkt | @AuctionTime Kirk Donsbach – Financial Analyst at StoneX https://www.stonex.com/ Follow on Facebook: @StoneXGroupInc Shaye Wanner – Host of Casual Cattle Conversation https://www.casualcattleconversations.com/ Follow on Facebook: @cattleconvos Contact Us with Questions or Concerns Have questions or feedback? Feel free to reach out via: Call/Text: 707-RANCH20 or 707-726-2420 Email: RanchItUpShow@gmail.com Follow us: Facebook/Instagram: @RanchItUpShow YouTube: Subscribe to Ranch It Up Channel: https://www.youtube.com/c/RanchItUp Catch all episodes of the Ranch It Up Podcast available on all major podcasting platforms. Discover the Heart of Rural America with Tigger & BEC Ranching, farming, and the Western lifestyle are at the heart of everything we do. Tigger & BEC bring you exclusive insights from the world of working ranches, cattle farming, and sustainable beef production. Learn more about Jeff 'Tigger' Erhardt & Rebecca Wanner (BEC) and their mission to promote the Western way of life at Tigger and BEC. https://tiggerandbec.com/ Industry References, Partners and Resources For additional information on industry trends, products, and services, check out these trusted resources: Allied Genetic Resources: https://alliedgeneticresources.com/ American Gelbvieh Association: https://gelbvieh.org/ Axiota Animal Health: https://axiota.com/multimin-campaign-landing-page/ Imogene Ingredients: https://www.imogeneingredients.com/ Jorgensen Land & Cattle: https://jorgensenfarms.com/#/?ranchchannel=view Medora Boot: https://medoraboot.com/ RFD-TV: https://www.rfdtv.com/ Rural Radio Network: https://www.ruralradio147.com/ Superior Livestock Auctions: https://superiorlivestock.com/ Transova Genetics: https://transova.com/ Westway Feed Products: https://westwayfeed.com/ Wrangler: https://www.wrangler.com/ Wulf Cattle: https://www.wulfcattle.com/

In this episode, host Lindsey Elizabeth Cortes, a sports dietitian and entrepreneur, delves into the world of female athlete nutrition with guest Nick Padula, a private practice sports dietitian and professor at the University of Southern California. They discuss the importance of personalized nutrition, the impact of dietary choices on performance, and the power of comprehensive testing, including continuous glucose monitors (CGMs), genomics, and microbiome analysis.   Nick shares his experiences working with various athletes, from boxers to endurance runners, and underscores how detailed nutrition data can significantly enhance training and recovery. Lindsey and Nick also explore practical approaches to fueling for both everyday athletes and elite sports performers, emphasizing the difference between generalized guidelines and individualized nutritional insights.   Episode Highlights: 01:24 Meet Nick Padula: Sports Dietician Extraordinaire 02:50 The Intersection of Clinical and Sports Nutrition 04:14 The Science and Ethics of Weight Cutting 09:52 Customizing Nutrition Through Testing 17:06 Understanding Genomic and Microbiome Testing 26:26 Addressing RED-S and Support Options 29:13 Understanding Gluten Intolerance 32:28 The Role of Continuous Glucose Monitors (CGMs) 35:37 Practical Applications of CGMs 42:05 The Importance of Recovery Nutrition 45:30 Exploring Nutrition Packages and Testing 47:07 The Impact of Environmental Toxins 53:31 Fun Questions and Final Thoughts Nick Padula has been a practicing Dietitian since 2015 as a clinical dietitian, a foodservice director. In addition to You Trition, LBC Nutrition, a dietetic consultant company, is a lecturer and coordinator with the University of Southern California Master’s in Nutrition program and Sports Dietitian for Cypress Junior College Athletics. ⁠   Nick studied nutrition and dietetics at Long Beach State University and received a Bachelor's degree in 2012 and Master's degree in Nutrition and Dietetics with a concentration in Sports Nutrition from Texas Tech University. ⁠In his practice he has worked with triathletes, professional boxers, endurance runners, professional soccer players, high school athletes, and the USC football and basketball teams. Nick is an avid runner, weightlifter, and golfer.   Connect with Nick: www.youtritionscience.com IG:@Youtrition_science Email: nick@youtritionscience.com   Resources and Links: For more information about the show, head to work with Lindsey on improving your nutrition, head to: http://www.lindseycortes.com/ Join REDS Recovery Membership: http://www.lindseycortes.com/reds WaveBye Supplements – Menstrual cycle support code LindseyCortes for 15% off: http://wavebye.co Previnex Supplements – Joint Health Plus, Muscle Health Plus, plant-based protein, probiotics, and more; code riseup for 15% off: previnex.com Female Athlete Nutrition Podcast Archive & Search Tool – Search by sport, condition, or topic: lindseycortes.com/podcast Female Athlete Nutrition Community – YouTube, Instagram @‌femaleathletenutrition, and private Facebook group

Synopsis: Host Rahul Chaturvedi sits down with Geoffrey Duyk, Chief Executive Officer of Grove Biopharma, for a wide-ranging conversation on navigating today's biotech macro headwinds and building companies that can translate breakthrough science into real patient impact. Dr. Duyk traces his journey from Harvard/Millennium/Exelixis operator to TPG investor and back to company creation, explaining how board dynamics, capital cycles, and policy shifts shape execution. They dig into why this cycle feels uniquely tough—patent cliffs, reimbursement uncertainty, NIH pressures—and who funds innovation in the meantime. Duyk outlines root causes of R&D inefficiency (misaligned capital vs. 20-year timelines, shaky preclinical predictability, costly trials, underused real-world data) and makes the case for rebuilding public trust and STEM education. Then, a deep dive on Grove Biopharma: precision polymer science that creates antibody-like, fully synthetic, cell-permeable protein mimetics to tackle historically “intractable” intracellular protein–protein interactions. Duyk shares design principles, why modular/orthogonal chemistry matters, predictable pharmacology, and lessons from fundraising and board management—plus why he's helping grow a Chicago-centered biotech ecosystem. Biography: Geoffrey M. Duyk, M.D., Ph.D. is the Chief Executive Officer of Grove Biopharma. Dr. Duyk has spent 30 years in the biotechnology industry as an entrepreneur, executive, and investor. Most recently, he was the Managing Partner at Circularis Partners, an investment firm he co-founded, focused on advancing the circular economy and promoting sustainability. Prior to that, Dr. Duyk was Managing Director and Partner at TPG Alternative & Renewable Technologies (ART)/TPG Biotechnology. Before joining TPG, Dr. Duyk served as a board member and President of R&D at Exelixis and was one of the founding scientific staff members at Millennium Pharmaceuticals, where he served as Vice President of Genomics. Earlier in his career, Dr. Duyk was an Assistant Professor in the Department of Genetics at Harvard Medical School (HMS) and an Assistant Investigator at the Howard Hughes Medical Institute (HHMI). While at HMS, he served as a co–principal investigator in the Cooperative Human Linkage Center, which was funded by the National Institutes of Health (NIH). Dr. Duyk is a trustee of Case Western Reserve University, where he serves on the executive committee. He previously served on the Board of Trustees of Wesleyan University and the Board of Directors of the Moffitt Cancer Center. He currently serves on the IR&E (Institutional Research and Evaluation) Committee at Moffitt, a key component of its External Advisory Committee (EAC). He was also a member of the Board of Directors of the American Society of Human Genetics (ASHG), and served as its treasurer. He is a member of the Life Sciences Advisory Board at Innovatus Capital Partners and the Scientific Advisory Board (SAB) for Lawrence Berkeley National Laboratory (DOE). Dr. Duyk previously served on the board of the Jackson Laboratory and on numerous NIH advisory committees. He is currently a Senior Advisor at Qiming Venture Partners (USA) and serves on the boards of Enno DC, Oobli, and Melanyze Dr. Duyk earned both his M.D. and Ph.D. from Case Western Reserve University and completed his medical and fellowship training at the University of California, San Francisco (UCSF). While at UCSF, he was a Lucille P. Markey Fellow and an HHMI postdoctoral fellow. He is a fellow of the American Association for the Advancement of Science.

Sally Wolf is back in the studio and this time we left cancer at the door. She turned 50, brought a 1993 Newsday valedictorian article as a prop, and sat down with me for a half hour of pure Gen X therapy. We dug into VHS tracking, Red Dawn paranoia, Michael J. Fox, Bette Midler, and how growing up with no helmets and playgrounds built over concrete somehow didn't kill us.We laughed about being Jewish kids in the suburbs, the crushes we had on thirty-year-olds playing teenagers, and what it means to hit 50 with your humor intact. This episode is part nostalgia trip, part roast of our own generation, and part meditation on the privilege of being alive long enough to look back at it all. If you ever watched Different Strokes “very special episodes” or had a Family Ties lunchbox, this one's for you.RELATED LINKSSally Wolf Official WebsiteSally Wolf on LinkedInSally Wolf on InstagramCosmopolitan Essay: “What It's Like to Have the ‘Good' Cancer”Oprah Daily: “Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis”Allure Breast Cancer Photo ShootTom Wilson's “Stop Asking Me the Question” SongFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What if the next major leap in aquaculture doesn't come from the ocean but from the genome? In this week's episode, we trace the story of genomic sequencing: from Darwin's first evolutionary trees to the breakthroughs that now let scientists map entire fish genomes in a single day. You'll learn how falling sequencing costs are opening the door to disease tracing, genetic selection, and smarter breeding programs that could redefine sustainability across aquaculture. For more aquaculture insights head to our Fish n' Bits blog.

Genomics in general practice: the PRECISE path forward by Podcast by Medcast

Associate Professor Jodie Ingles leads Australia’s National Registry for Genetic Heart Disease, bringing together patients and families to improve diagnosis, treatment and understanding of inherited heart conditions through cutting-edge genomic research. Prof. Ingles and her team at the Garvan Institute are researching the genetic causes of inherited heart diseases, such as cardiomyopathies and arrhythmias, which can lead to sudden cardiac death. Their work focuses on identifying the underlying genetic mutations that put individuals and families at risk, using advanced genomic sequencing and data from the National Registry for Genetic Heart Disease. By combining genetic insights with clinical information, they aim to improve diagnosis, guide personalised treatment, and inform family screening. The team also studies how families experience and respond to genetic testing, helping to shape better care and counselling for affected Australians.See omnystudio.com/listener for privacy information.

This week we look at the rapidly advancing field of genomics, which is becoming increasingly relevant to everyday primary care. Emma speaks to Dr Jude Hayward and Dr Imran Rafi, who are the Royal College of GPs' joint clinical representatives for genomics. Jude is a GP with an extended role in genomic medicine and Imran is a reader in primary care and genomics at St. George's University in London.Jude and Imran discuss the most significant changes genomics is set to bring over the next decade, including its potential use in predicting risk for common conditions, rise of pharmacogenomics and whether the government's 10-year plan's vision for the role of genomics is realistic.They also talk about some of the practical challenges facing GPs, such as how to handle patients presenting with results from direct-to-consumer genetic tests, the ethical considerations around data and consent, and the importance of ensuring advances in genomics help to narrow rather than widen health inequalities.And they also explore the opportunities for GPs to develop an extended role in this fascinating area of medicine.This episode was presented by GPonline editor Emma Bower. It was produced by Czarina Deen.Useful linksGeNotes - genomics notes for cliniciansGP with extended role in clinical genetics/genomics - RCGP frameworkRCGP eLearning - Genomics toolkitRCGP position statement on direct to consumer genomics testing Hosted on Acast. See acast.com/privacy for more information.

Dr. Nikki Maphis didn't just lose a grant. She lost a lifeline. An early-career Alzheimer's researcher driven by her grandmother's diagnosis, Nikki poured years into her work—only to watch it vanish when the NIH's MOSAIC program got axed overnight. Her application wasn't rejected. It was deleted. No feedback. No score. Just gone.In this episode, Oliver Bogler pulls back the curtain on what happens when politics and science collide and promising scientists get crushed in the crossfire. Nikki shares how she's fighting to stay in the field, teaching the next generation, and rewriting her grant for a world where even the word “diversity” can get you blacklisted. The conversation is raw, human, and maddening—a reminder that the real “war on science” doesn't happen in labs. It happens in inboxes.RELATED LINKS:• Dr. Nikki Maphis LinkedIn page• Dr. Nikki Maphis' page at the University of New Mexico• Vanguard News Group coverage• Nature article• PNAS: Contribution of NIH funding to new drug approvals 2010–2016FEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Nursing EDge Unscripted, hosts Dr. Kellie Bryant and Dr. Raquel Bertiz talk with Dr. Deborah Himes and Dr. Cindy Snyder about the critical role of genomics in nursing education and practice. The guests emphasize that genomics is not a specialty but an essential part of everyday nursing, influencing risk assessment, treatment decisions, and patient outcomes. They share practical strategies for integrating genomics into curricula, such as using family history tools, case studies, and analogies to make complex concepts understandable for patients and students. The conversation highlights updated nursing competencies, available resources, and the importance of preparing nurses to meet national expectations for genomic literacy. The episode concludes by stressing that genomics, epigenetics, and pharmacogenomics shape how diseases are understood and treated, making it vital that all nurses are prepared to apply these concepts in practice.Learn more about genomics:International Society of Nurses in Genetics (ISONG) Genomics Education Resources Repository: https://www.isong.org/ed-resources-repositoryThis repository provides an extensive list of education and professional organizations for nurses/educators needing "self-guided learning" or resources in genomics.ISCC-PEG FAQ series: https://www.genome.gov/For-Health-Professionals/Provider-Genomics-Education-Resources/nursing-genomics-faqAmerican Nurses Association &  International Society of Nurses in Genetics (2025). Genomics Nursing: Scope and Standards of Practice, 3rd Edition. https://www.nursingworld.org/nurses-books/ana-books/ebook-genomics-nursing-scope-and-standards-of-practice-3rd-editionNursing Genomics FAQs. The Nursing Genomics Project Group of the Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC-PEG) created a Nursing Genomics FAQ to address how to integrate genomics into education and practice. www.genome.gov/For-Health-Professionals/Provider-Genomics-Education-Resources/nursing-genomics-faqLInking Nursing Knowledge And GEnomics (LINKAGE) is an online source with educational content about foundational genomic concepts in the context of nursing practice.Free content faculty can assign to students and faculty-only resources. https://linkage.trubox.ca/ Calzone, K. A., Stokes, L., Peterson, C., & Badzek, L. (2024). Update to the essential genomic nursing competencies and outcome indicators. Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing, 56(5), 729–741. https://doi.org/10.1111/jnu.12993Dedicated to excellence in nursing, the National League for Nursing is the leading organization for nurse faculty and leaders in nursing education. Find past episodes of the NLN Nursing EDge podcast online. Get instant updates by following the NLN on LinkedIn, Facebook, Instagram, Bluesky, and YouTube. For more information, visit NLN.org.

In this explainer episode, we've asked Dr Emily Perry, research engagement manager at Genomics England, to explain what the Genomics England Research Environment is. You can also find a series of short videos explaining some of the common terms you might encounter about genomics on our YouTube channel. You can listen to the previous episodes mentioned in this podcast How has a groundbreaking genomic discovery impacted thousands worldwide? What is the National Genomic Research Library If you've got any questions, or have any other topics you'd like us to explain, let us know on podcast@genomicsengland.co.uk. You can download the transcript or read it below. Florence: What is the Genomics England Research Environment? My name is Florence Cornish and I'm here with Emily Perry, Research Engagement Manager at Genomics England, to find out more. So Emily, before we dive into the Research Environment, let's set some context. Could you explain what Genomics England is aiming to do as an organisation? Emily: So, Genomics England provides genome sequencing in a healthcare setting for the National Health Service in England. As we sequence genomes for healthcare, the benefit is that we can also put that genomic and clinical data out for research in a controlled manner, and then that can also feed back into healthcare as well. So, it's really, this kind of cyclical process that Genomics England is responsible for. Florence: And so, what do we mean when we say Research Environment? Emily: So, the Research Environment is how our researchers can get access to that clinical and genomic data that we get through healthcare. So, it's a controlled environment, it's completely locked down, so it's kind of like a computer inside a computer. And in there, the researchers can access all of the data that we have and also a lot of tools for working with it in order to do their research. We refer to the data as the National Genomics Research Library, or the NGRL. The NGRL data is provided inside the Research Environment Florence:  So you mentioned the National Genomic Research Library. If any listeners want to learn more about this, you can check out our previous Genomics 101 podcast: What is the National Genomic Research Library? And so Emily, could you talk about what kind of data is stored in this library? Emily: So the library is made up of both genomic data and clinical data, which the researchers use alongside each other. The genomic data includes what we call alignments, which is where we match the reads from sequencing onto a reference sequence, and variants, which is where we identify where those alignments differ from the reference sequence, and this is what we are looking for in genomic research. The clinical data includes the data that was taken from our participants at recruitment, so details of the rare disease, the cancer, that they have, but also medical history data. So, we work with the NHS and we're able to get full medical history for our participants as well. This is all fully anonymised, so there's no names, there's no dates of birth, there's no NHS numbers. It's just these identifiers which are used only inside the Research Environment and have no link to the outside world. Florence: And so how is this clinical and genomic data secured? Emily: So, as I said there's no names, there's no NHS numbers, there's no dates of birth.  And we have very strict criteria for how people can use the data. So researchers, in order to get access to the Research Environment, they have to be a member of a registered institution, they have to submit a project proposal for what it is that they want to study with the data. There's also restrictions on how they can get the data out, so they do all their research inside, there's no way that they can do things like copy and paste stuff out or move files. The only way that they can get data out of the Research Environment is going through a process called Airlock, which is where they submit the files that they want to export to our committee, who then analyse it, check that it's in accordance with our rules and it protects our participants' safety and that only then would they allow them to export it. Florence: Who has access to the Research Environment? Emily: We have researchers working with the Research Environment all over the world. There's 2 kind of major groups. One of them is academia, so this will be researchers working in universities and academic institutions. The other side of it would is industry - so this will be biotech, startups, pharma companies, things like that. Florence: And finally, can you tell us about some of the discoveries that have been made using this data? Emily: There's lots of really cool things that have come out of the Research Environment.  A recent story that came out of the Research Environment was the ReNU syndrome, it was initially just one family that they identified this in, and they were able to extend this discovery across and identify huge numbers of individuals who had this same disorder because they had their genomes within the Research Environment. Florence: You can hear more about this research in our previous Behind the Genes podcast: How has a groundbreaking genomic discovery impacted thousands worldwide? So, we'll wrap up there. Thank you so much, Emily, for sharing more about what we mean by the Genomics England Research Environment. If you'd like to hear more explain episodes like this, you can find them on our website, at www.genomicsengland.co.uk or wherever you get your podcasts. Thank you for listening.  

Send us a textChristian Maugee is a PhD Candidate at the University of Florida, in Genetics and Genomics ( http://www.vulpelab.net/graduate-and-undergrad-students.html ), where his research explores how gene expression differs in the hearts of individuals with Friedrich's Ataxia (FA), a rare, progressive neurodegenerative disease.  His work could lead to new insights into the cardiac complications that can be associated with FA and how to potential treat them better.Christian's dissertation work is focused on identifying gene modulators of the transcriptional phenotype of FA in human induced pluripotent stem cells differentiated into cardiomyocytes (hPSC-CMs). He accomplishes this through use of a novel method: Perturb-seq - a CRISPR screen coupled with single cell RNA sequencing (scRNA-seq) readout. Christian is driven by much more than academic curiosity, as he brings a unique and deeply human perspective to his work as someone living with FA. He doesn't just study the challenges faced by those with disabilities; he lives them. His work is not only informed by data and theory, but by resilience, authenticity, and a commitment to making research more inclusive and impactful.In the lab, Christian loves mentoring, and outside of the lab he loves fundraising and raising awareness for FA, mainly through FARA ( https://www.curefa.org/ ) and MDA ( https://www.mda.org/disease/friedreichs-ataxia ).Christian received a Bachelor's degree in Cell/Cellular and Molecular Biology, from the University of South Florida.Important Episode Link - The Science Guy: Back In The Lab For FAhttps://www.ataxia.org/billnye-for-fa/#ChristianMaugee #FriedreichsAtaxia #UniversityOfFlorida #Genetics #Genomics #MolecularBiology #UniversityOfSouthFlorida #Frataxin #MitochondrialDysfunction #OxidativeStress #Neurodegeneration #AmyotrophicLateralSclerosis #FrontotemporalDementia #Dystonia #HypertrophicCardiomyopathy #DilatedCardiomyopathy #Cardiomyocytes #InducedPluripotentStemCells #Epigenetic #BillNye #Mitochondria #RareDisease #Neurology #Biogen #Omaveloxolone #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Carla Tardiff has spent 17 years as the CEO of Family Reach, a nonprofit that shouldn't have to exist but absolutely does—because in America, cancer comes with a price tag your insurance doesn't cover.We talk about shame, fear, burnout, Wegmans, Syracuse, celebrity telethons, and the godforsaken reality of choosing between food and treatment. Carla's a lifer in this fight, holding the line between humanity and bureaucracy, between data and decency. She's also sharp as hell, deeply funny, and more purpose-driven than half of Congress on a good day.This episode is about the work no one wants to do, the stuff no one wants to say, and why staying angry might be the only way to stay sane.Come for the laughs. Stay for the rage. And find out why Family Reach is the only adult in the room.RELATED LINKSFamily ReachFinancial Resource CenterCarla on LinkedInMorgridge Foundation ProfileAuthority Magazine InterviewSyracuse University FeatureFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join us for an insightful conversation about the intersection of technology and healthcare with Pallavi Ranade from Intermountain Health and Janae Sharp. In this episode, we explore how healthcare organizations can effectively measure return on investment while keeping patient-centered outcomes at the forefront. From the hidden costs of technology implementation to the promise of AI and genomics, our guests share practical wisdom on navigating innovation challenges, allocating resources strategically, and ensuring that technological advances truly benefit both patients and clinicians. Whether you're a healthcare leader weighing your next tech investment or simply curious about the future of healthcare delivery, this discussion offers valuable perspectives on making technology work for everyone in the healthcare ecosystem.Pallavi Ranade-Kharkar, PhD, MS, FAMIA, Director of Research Informatics Genomics, Intermountain HealthJanae Sharp, Founder, The Sharp Index

Ever wished you could get breeding values on your commercial Merinos without having to record weights, dates or pedigrees?This week, we're launching neXtPredict, our brand new genomic tool that lets you go straight from DNA to breeding values with just a simple TSU sample.Developed in partnership with Weatherbys Scientific, neXtPredict provides base genomic breeding values, parentage, poll/horn testing and a flock profile for Merino breeders. It's powered by the MerinoSelect database and backed by MLA-funded research through AGBU and Sheep Genetics.To announce the launch this week on the podcast, Ferg chats with Tamarah Luxton, Territory Manager at Weatherbys Scientific. Tamarah shares the story of Weatherbys' journey from managing thoroughbred pedigrees in Ireland to providing cutting-edge genomic testing for livestock across Australia. neXtPredict has three service tiers, designed to suit everyone from large commercial breeders to data-driven operations wanting deeper insights.CORE gives you access to the neXtPredict Portal, where you can view gBVs, parentage, poll/horn, flock profiles and indexes, and filter or rank animals on standard industry indexes or generic neXtgen Agri indexes.PLUS includes everything in CORE, plus trait correlation analysis, the creation of custom indexes, and one-on-one support from the neXtgen Agri team.PRO adds long-term data storage, the ability to include non-genomic traits (like wool quality or dag scores), view multi-year data, and work directly with our consultants on testing strategies and optimisation.If you are interested in using neXtPredict, get in touch with us here at neXtgen Agri:info@nextgenagri.comOr with Weatherbys Scientific:tluxton@weatherbys.com.auHead Shepherd is brought to you by neXtgen Agri International Limited. We help livestock farmers get the most out of the genetics they farm with. Get in touch with us if you would like to hear more about how we can help you do what you do best: info@nextgenagri.com.Thanks to our sponsors at MSD Animal Health and Allflex, and Heiniger Australia and New Zealand. Please consider them when making product choices, as they are instrumental in enabling us to bring you this podcast each week.Check out Heiniger's product range HERECheck out the MSD range HERECheck out Allflex products HERE

In this episode of Disruption/Interruption, host KJ sits down with Jim Foote, CEO and founder of First Ascent Biomedical. Jim shares his personal journey from technology executive to cancer care innovator, after his son’s diagnosis changed his life. Discover how he’s disrupting the status quo in oncology with AI-driven, personalized medicine that’s giving new hope to patients and families. Key Takeaways: The Problem with Standard Cancer Care [3:53]The standard of care treats patients as if they are the same, but everyone is unique. This approach works two-thirds of the time, but leaves one-third of patients with few options. Functional Precision Medicine [13:04]Jim’s company tests up to 152 FDA-approved drugs on a patient’s biopsy to find the most effective treatment, providing doctors with data-driven options tailored to each individual. AI and Technology are Transforming Oncology [28:05]Advances in AI, robotics, and cloud computing have converged, making personalized cancer treatment faster, more affordable, and more effective than ever before. Impact and Future Vision [26:51]Jim’s goal is for every cancer patient to receive individualized treatment from the moment of diagnosis, improving outcomes and reducing unnecessary side effects. Quote of the Show (14:40):“I literally have gone from trying and hoping to testing and choosing.” — Jim Foote Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Jim Foote: LinkedIn: http://www.linkedin.com/in/jim-foote Company Website: https://firstascentbiomedical.com/ How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

Jennifer J. Brown is a scientist, a writer, and a mother who never got the luxury of separating those roles. Her memoir When the Baby Is Not OK: Hopes & Genes is a punch to the gut of polite society and a medical system that expects parents to smile through trauma. She wrote it because she had to. Because the people who gave her the diagnosis didn't give her the truth. Because a Harvard-educated geneticist with two daughters born with PKU still couldn't get a straight answer from the very system she trained in.We sat down in the studio to talk about the unbearable loneliness of rare disease parenting, the disconnect between medical knowledge and human connection, and what it means to weaponize science against silence. She talks about bias in the NICU, the failure of healthcare communication, and why “resilience” is a lazy word. Her daughters are grown now. One's a playwright. One's an artist. And Jennifer is still raising hell.This is a conversation about control, trauma, survival, and rewriting the script when the world hands you someone else's lines.Bring tissues. Then bring receipts.RELATED LINKS• When the Baby Is Not OK (Book)• Jennifer's Website• Jennifer on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode's Community Champion Sponsor is Ossur. To learn more about their ‘Responsible for Tomorrow' Sustainability Campaign, and how you can get involved: CLICK HEREEpisode Overview: Addiction doesn't announce itself- it emerges silently, often after a routine medical procedure. Our next guest, James Piacentino, is changing this reality as CEO and Co-Founder of Thrive Genetics. With over 20 years in healthcare technology and two successful startup exits under his belt, James brings both personal experience and professional expertise to this mission. After losing his father to opioid addiction following a routine surgery, James dedicated his career to ensuring others wouldn't face the same tragedy. By combining cutting-edge genomics with behavioral psychology, Thrive Genetics helps physicians understand a patient's addiction risk before prescribing pain medication. Join us to discover how James and his team are pioneering personalized addiction risk management, transforming how healthcare systems approach prevention, and working to spare millions of families from generational trauma. Let's go!Episode Highlights:Curiosity as the foundation for innovation: James emphasizes that deep curiosity about solving meaningful problems is the key driver that gets him out of bed every morning and the most important quality he looks for in team members.Personal tragedy sparking a mission: After losing his father to opioid addiction following a 1982 car accident and back surgery, James dedicated his career to preventing others from experiencing the same generational trauma.Staggering gap in care: Up to 25% of patients undergoing high-pain procedures become addicted to prescribed opioids, yet no proactive addiction risk assessment exists before prescribing pain medication.Science-backed solution: Thrive Genetics combines 10 years of research and over $50M in NIH grants to create addiction risk scores based on both genetic predisposition (50%) and behavioral factors (50%).Thinking beyond the individual: James' North Star is reaching billions of people by preventing not just individual addiction cases, but stopping generational family trauma before it starts.About our Guest: Thrive Genetics is led by Co-Founder and CEO, James J. Piacentino, MBA, a healthcare technology entrepreneur with over 20 years in tech and life sciences. A graduate of Northwestern University's Kellogg School of Management, James has built and sold two prior startups, published in the Harvard Business Review, and held senior leadership roles at SAP. He is mentored by Harry Kraemer, former CEO of Baxter International and Kellogg Professor of Management.Links Supporting This Episode: Thrive Genetics Website: CLICK HEREJame Piacentino LinkedIn page: CLICK HEREThrive Genetics LinkedIn: CLICK HEREMike Biselli LinkedIn page: CLICK HEREMike Biselli Twitter page: CLICK HEREVisit our website: CLICK HERESubscribe to newsletter:

This week, Dr. Debbie Hipps, a pioneering GP and primary care lead, joins Ben to explore how genomic medicine is transforming general practice. From enhancing risk assessments, family history evaluations, and cancer treatments to driving the NHS's shift from reactive to preventative care, Debbie highlights the urgent need for GPs and pharmacists to upskill in this fast-evolving field. We discuss practical tools like the Genomics Education Programme, real-world examples such as managing Lynch syndrome, and the broader challenges of integrating genomics into primary care, while looking ahead to a future of more precise, personalised treatments. Introduction (00:10) Genomic medicine (01:43)  Genomics in the 10 year plan (02:28)  How is genomic medicine being used in general practice now? (03:21) What makes something genomic medicine? (07:02) What genetic tests are available for patients? (07:53) Examples of practices who regularly use the testing.. (11:45) The near future.. (13:10) Staying up to date.. (16:13)  Services across the UK.. (17:19)  Resources (19:01)  Can it make the shift from treatment to prevention.. (19:31)  Access the RCGP Genomic Toolkit and Curriculum Guidance here. Access the Genomics Education Programme: Genomics in Primary Care here. Access the Genetic Test Ordering in Primary Care Resources here. Access the Genomic notes for clinicians here. Visit the Gateway C Course: The role of Genomics in Primary Care here. Visit the Futurelearn: the Future of Genetics in Medicine Online Course here. Download the Genomics information on an App here (Please note - only currently available for SE, NThames and East regions) North Thames GMSA Educational Resources can be accessed here. eLearning for Health Genomics in Healthcare is found here. For all enquiries about the Ockham podcast, please contact Ben Gowland here.

This episode of Standard Deviation features Oliver Bogler in conversation with Dr Na Zhao, a cancer biologist caught in the crossfire of science, politics, and survival. Na's life reads like a brutal lab experiment in persistence.She grew up in China, lost her mother and aunt to breast cancer before she turned twelve, then came to the United States to chase science as both an immigrant and a survivor's daughter. She worked two decades to reach the brink of independence as a cancer researcher, only to watch offers and grants vanish in the political chaos of 2025.Oliver brings her story into sharp focus, tracing the impossible climb toward a tenure-track position and the human cost of a system that pulls the ladder up just as people like Na reach for it. This conversation pulls back the curtain on the NIH funding crisis, the toll on early-career scientists, and what happens when personal tragedy fuels professional ambition.Listeners will walk away with a raw sense of how fragile the future of cancer research really is, and why people like Na refuse to stop climbing.RELATED LINKSDr Zhao at Baylor College of MedicineDr Zhao on LinkedInDr Zhao's Science articleIndirect Costs explained by US CongressFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Katie Henry has seen some things. From nonprofit bootstraps to Big Pharma boardrooms, she's been inside the machine—and still believes we can fix it. We go deep on her winding road from folding sweaters at J.Crew to launching a vibrator-based advocacy campaign that accidentally changed the sexual health narrative in breast cancer.Katie doesn't pull punches. She's a born problem solver with zero tolerance for pink fluff and performative empathy. We talk survivor semantics, band camp trauma, nonprofit burnout, and why “Didi” is the grandparent alter ego you never saw coming.She's Murphy Brown with a marimba. Veronica Sawyer in pharma. Carla Tortelli with an oncology Rolodex. And she still calls herself a learner.This is one of the most honest, hilarious, and refreshingly real conversations I've had. Period.RELATED LINKS:Katie Henry on LinkedInKatie Henry on ResearchGateLiving Beyond Breast CancerNational Breast Cancer CoalitionFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

INTERVIEW: Stephen Robertson on Māori genomics & public health + talk @Ombrellos by Zac Hoffman on Radio One 91FM Dunedin

Dr. Deanna Saylor and Dr. Senjuti Saha discuss colonialism in global health and the importance of pathogen genomics.  Show reference:  https://www.thelancet.com/journals/landig/article/PIIS2589-7500(24)00091-8/fulltext

Michael welcomes  Dr. Sandy Rolfe, WEDI's Genomics Workgroup Chair Clinical Content Lead, InterQual, Optum Insight Lesley Berkeyheiser, WEDI's Privacy & Security Workgroup Co-Chair, Assessor with DirectTrust Thanh Thien Nguyen, WEDI's Privacy & Security Workgroup Co-Chair, Executive Director, Kaiser Permanente to discuss their workgroups working together to spotlight the intersection between direct to consumer (DTC) genetic tests and some different privacy and security issues associated with these types of tests. The two workgroups collaborated to develop a Fact Sheet to help consumers take action to protect their data, available here- https://www.wedi.org/2025/07/12/direct-to-consumer-genetic-dna-testing-actions-consumers-can-take-to-protect-their-health-data/  Current regulations and requirements Thanh Thien references in the episode HIPAA Privacy Rule- https://www.hhs.gov/hipaa/for-professionals/privacy/index.html HIPAA Security Rule- https://www.hhs.gov/hipaa/for-professionals/security/index.html Genetic Information Nondiscrimination Act of 2008- https://www.govinfo.gov/content/pkg/PLAW-110publ233/pdf/PLAW-110publ233.pdf Federal Trade Commission Act- https://www.ftc.gov/legal-library/browse/statutes/federal-trade-commission-act California Consumer Privacy Act of 2018- https://oag.ca.gov/privacy/ccpa California Privacy Rights Act- https://thecpra.org/ State Privacy Law Tracker- https://iapp.org/resources/article/us-state-privacy-legislation-tracker/

Dr. Deanna Saylor talks with Dr. Senjuti Saha about colonialism in global health and the importance of pathogen genomics.  Read the related article in The Lancet.  Disclosures can be found at Neurology.org. 

In this episode, we talk with two authors who have papers featured in the special issue of the Journal of Genetic Counseling on Research Methods in Genetic Counseling. In the first segment we explore implementation science and its utilization in bridging the gap between research and clinical practice. In our second segment, we talk to an author about retrospective chart reviews and the benefits and drawbacks of this methodology.   Segment 1: A guide to utilizing implementation science for genetic counseling   Alanna Kulchak Rahm is a certified genetic counselor and implementation scientist with a PhD in Health and Behavioral Science. She has spent her career specializing in the implementation of genomics and precision health in healthcare systems. For over 25 years, she has conducted research on the utilization of genetic information by individuals and healthcare systems, new paradigms for identifying individuals with genomic risk, and new service delivery models for genomic testing. She has been a driver for the integration of implementation science and patient engagement to understand and study the integration of genomics into the learning health system, and is a tireless advocate of implementation science in genetic counseling. She has participated in and led many workshops and trainings on implementation science in genetics, serving as a faculty mentor for the NIH Training in Dissemination and Implementation Research in Cancer (TIDIRC) and recently as a co-lead of the Training in Dissemination and Implementation Research in Genomics and Precision Public Health (TIDIR-GPPH). She is currently a Program Director in the Division of Genomic Medicine at the National Human Genome Institute (NHGRI) where she directs the Network of Genomics-Enabled Learning Health Systems and other programs and continues to advance the integration of implementation science and genomics.   In this segment we discuss: Implementation science (IS) as a bridge between research and clinical practice in genetic counseling Misconceptions about IS, key frameworks like RE-AIM, and practical applications in daily work Using IS to identify and reduce inequities in genomic medicine Future integration of IS into training, research, and professional practice Link to the 2025 annual conference on dissemination and implementation    Segment 2: Leveraging hindsight: A retrospective chart review how-to for genetic counselors   Dr. Ramsey is the Section Chief of Individualized Therapeutics in the Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation at Children's Mercy. She is leading the implementation of a pharmacogenomics program that is fully integrated with the electronic health record, developing model-informed decision support for several medications, and Co-director of their Pediatric Clinical Pharmacology Fellowship Program. Before joining Children's Mercy, Dr. Ramsey was an Associate Professor and co-director of the Genetic Pharmacology Service at Cincinnati Children's Hospital. She completed her postdoctoral fellowship in Pharmacogenetics at St. Jude Children's Research Hospital and received her PhD in Molecular, Cellular, Developmental Biology and Genetics from the University of Minnesota – Twin Cities. Dr. Ramsey is interested in all aspects of pharmacogenetics, from basic research to implementation in patient care.   In this segment we discuss: The role of retrospective chart reviews in genetic counseling research Common pitfalls such as unclear aims, time demands, and data extraction challenges Strategies for success, including SOPs, REDCap, and multidisciplinary collaboration Lessons learned on refining criteria, ensuring data quality, and team engagement   Would you like to nominate a JoGC article to be featured in the show? If so, please fill out this nomination submission form here. Multiple entries are encouraged including articles where you, your colleagues, or your friends are authors.   Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.    For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.    Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.    DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. Our current intern is Stephanie Schofield. 

What if prostate cancer surgery meant fewer incisions, faster recovery, and more precise cancer control? Today I'm joined by Dr. Michael D. Stifelman, Chair of Urology at Hackensack University Medical Center and a pioneer in robotic surgery with 4,000+ robotic procedures. We unpack how single-port robotics, real-time margin assessment, and AI are reshaping outcomes—while protecting continence and erections.Dr. Stifelman traces robotics from the early-2000s “pioneer phase” (and heavy skepticism) to today's standard of care, explaining why reproducibility, visualization, and tissue-sparing dexterity made the difference. We compare surgery vs. radiation (and focal therapies), when each shines, and why sequencing often matters—especially in higher-risk disease. He shares emerging tech like single-port prostatectomy, intra-operative margin evaluation (e.g., Histo-style scanning), quantitative surgical analytics, and even remote robotic assistance. We also talk “trifecta” outcomes, the role of genomics in Gleason 7 decision-making, and why lifestyle medicine and optimizing the tumor micro-environment go hand-in-hand with any treatment.Time-Stamped Highlights00:00 – Why fewer incisions + faster recovery are now real in prostate surgery05:40 – Work–life changes that improved health (sleep, exercise, biking)09:10 – Open vs. robotic: why reproducibility (teachability) matters11:05 – Robotics adoption curve: from early resistance to mainstream19:05 – Outcomes today: continence and erections after modern surgery20:10 – “Yes, I'm a surgeon—and here's my bias.” Radical honesty with patients22:05 – Offering the full menu: surveillance, focal (HIFU/cryotherapy), surgery, SBRT, proton25:40 – High-risk (Gleason 8–9): why surgery-first can preserve options & avoid long ADT34:00 – Dexterity & visualization: why robots spare nerves with less trauma35:10 – Real-time margin assessment during surgery to reduce positives40:00 – The “trifecta” (cancer control, continence, erections) and patient priorities42:10 – Genomics to risk-stratify Gleason 7 and guide surveillance vs. treatment45:00 – Future: nerve activation mapping & fluorescence to “light up” cancer46:10 – Single-port prostatectomy: smaller access, faster return of function (select patients)49:00 – Quantifying surgery with analytics; tele-mentoring & remote console potential52:30 – How to find Dr. Stifelman & closing advice

Sophie Sargent walked into the studio already owning the mic. A pandemic-era media rebel raised in New Hampshire, trained in Homeland Security (yep), and shaped by rejection, she's built a career out of DM'ing her way into rooms and then owning them. At 25, she's juggling chronic illness, chronic overachievement, and a generation that gets dismissed before it even speaks.We talk Lyme disease, Lyme denial, and the healthcare gaslighting that comes when you “look fine” but your body says otherwise. We dive into rejection as a career accelerant, mental health as content porn, and what it means to chase purpose without sacrificing identity. Sophie's a former morning radio host, country music interviewer, and Boston-based creator with a real voice—and she uses it.No fake podcast voice. No daddy-daughter moment. Just two loudmouths from different planets figuring out what it means to be seen, believed, and taken seriously in a system designed to do the opposite.Spoiler: She's smarter than I was at 25. And she'll probably be your boss someday.RELATED LINKSSophie on InstagramSophie on YouTubeSophie on LinkedInMedium article: “Redefining Rejection”See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What happens when you hand a mic to the most extroverted, uncensored Gen Z career coach in New York? You get Olivia Battinelli—adjunct professor, student advisor, mentor, speaker, and unfiltered truth-teller on everything from invisible illness to resume crimes.We talked about growing up Jewish-Italian in Westchester, surviving the Big Four's corporate Kool-Aid, and quitting a job after 7 months because the shower goals weren't working out. She runs NYU Steinhardt's internship program by day, roasts Takis and “rate my professor” trolls by night, and somehow makes room for maple syrup takes, career coaching, and a boyfriend named Dom who sounds like a supporting character from The Sopranos.She teaches kids how to talk to humans. She's allergic to BS. And she might be the most Alexis Rose-meets-Maeve Wiley-mashup ever dropped into your feed. Welcome to her first podcast interview. It's pure gold.RELATED LINKS:Olivia Battinelli on LinkedInOlivia's Liv It Up Coaching WebsiteOlivia on InstagramNYU Steinhardt Faculty PageFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On today's Unemployable, we tackle the hard stuff: why cancer remains our biggest health challenge, why water quality may define the next global conflict, how outbreaks re-enter the U.S. (measles, dengue, bioterror), what COVID actually taught us, and where AI and genomics help—or create new risks. Along the way we talk access to care, compounding vs. brand-name drugs, GLP-1s (Ozempic/Wegovy), and the habits that really move the needle: sleep, strength, hydration, and walking with purpose. My guest is a former U.S. Assistant Secretary for Health and four-star admiral in the U.S. Public Health Service with leadership roles spanning MD Anderson's Moon Shots, WHO, and federal response teams for anthrax and Ebola. It's a masterclass in population health, plain talk, and what leaders should actually do next. Timestamps below. If this helps you think clearer and lead better, hit subscribe and share it with one person who needs it today. Disclaimers: This show is educational only. Nothing here is medical advice. Talk to your doctor before making decisions about screening, vaccines, medications, or treatment. Resources mentioned: • Joxel Garcia's books on Amazon • St. Jude Children's Research Hospital • MD Anderson Moon Shots • CDC/WHO resources on vaccines & outbreaks 

On today's Unemployable, we tackle the hard stuff: why cancer remains our biggest health challenge, why water quality may define the next global conflict, how outbreaks re-enter the U.S. (measles, dengue, bioterror), what COVID actually taught us, and where AI and genomics help—or create new risks. Along the way we talk access to care, compounding vs. brand-name drugs, GLP-1s (Ozempic/Wegovy), and the habits that really move the needle: sleep, strength, hydration, and walking with purpose. My guest is a former U.S. Assistant Secretary for Health and four-star admiral in the U.S. Public Health Service with leadership roles spanning MD Anderson's Moon Shots, WHO, and federal response teams for anthrax and Ebola. It's a masterclass in population health, plain talk, and what leaders should actually do next. Timestamps below. If this helps you think clearer and lead better, hit subscribe and share it with one person who needs it today. Disclaimers: This show is educational only. Nothing here is medical advice. Talk to your doctor before making decisions about screening, vaccines, medications, or treatment. Resources mentioned: • Joxel Garcia's books on Amazon • St. Jude Children's Research Hospital • MD Anderson Moon Shots • CDC/WHO resources on vaccines & outbreaks 

Host Matt chats with American genetic counsellor Dr Lisa Schwartz about the evolving professional identity of genetic counsellors, the role of networking and qualitative research (including authors' positionality), and how clinical training translates into lab, policy and education roles. They also swap stories about travel, outdoor winery concerts, Stevie Nicks, their dogs, and advances in genetics such as Duchenne research, while discussing how training and definitions may need to change as the profession grows.

In this explainer episode, we've asked Dr Nour Elkhateeb, clinical fellow at Genomics England and clinical geneticist for the NHS, to explain the role of a clinical geneticist. The previous episode mentioned in the conversation is linked below. What is the diagnostic odyssey? You can also find a series of short videos explaining some of the common terms you might encounter about genomics on our YouTube channel. If you've got any questions, or have any other topics you'd like us to explain, let us know on podcast@genomicsengland.co.uk. You can download the transcript or read it below. Florence: What is a clinical geneticist? My name is Florence Cornish and I'm here with Nour Elkhateeb, clinical geneticist for the NHS and fellow at Genomics England, to find out more. So, Nour, before we dive into talking about clinical geneticists, could you explain what we mean by the term genetics? Nour: Hi Florence, so at its heart, genetics is the study of our genes and how they are passed down through families. Think of your genome as a huge, incredibly detailed instruction manual for building and running your body. This manual is written in a specific language, DNA, which is made up of millions of letters arranged in a specific order.  And here is the interesting part, we all have tiny differences in our genetic spelling, which is what makes each of us unique.  But sometimes a change in the instructions, a spelling mistake in a critical place, can affect health. Genetics is all about learning to read that manual, understand how changes in it can cause disease, how it's passed down through families and finding ways to help.   Florence: And so, what kind of thing does a geneticist actually do? Nour: Well, the term geneticist can cover a few different roles, which often work together. Crudely speaking, you can think of two main types, laboratory geneticists and clinical geneticists.   Laboratory geneticists are the incredible scientists who work behind the scenes. When we send a blood sample for genomic sequencing, they are the ones who use amazing technology to read the billions of letters in that person's instruction manual. The job is to find the one tiny spelling mistake among those billions of letters that might be causing a health problem.  Clinical geneticists like me are medical doctors specialised in the field of genetics, and we work face-to-face with patients and families in a hospital or a clinic setting. You can think of us as the bridge between the incredibly complex science of the genomics lab and the real-life health journey of the person in front of them. We diagnose, manage and provide support for individuals and families who are affected by or at risk of genetic conditions. And we translate that complex genetic information into meaningful information for the patient, the family and the other doctors as well.  Florence: So, let's talk a little bit more about clinical geneticists. What stage of someone's genomics journey are they likely to see you? What are some typical reasons they might get referred, for example?  Nour: That's a really good question. So, people actually can be seen by clinical geneticists at almost any stage of life, and for many different reasons. Let me give you some examples.  We see a lot of babies and children. A family may be referred to us if their baby is born with health problems that do not have a clear cause, or if a child is not developing as expected. And sometimes families may have been searching for answers for years, or what we call a diagnostic odyssey, but no one has been able to find a single unifying diagnosis to explain their challenges. And our job is to see if there is a genetic explanation that can connect all the dots.  Florence: You touched there on the diagnostic odyssey, and I know we don't have time to dive into that right now, but if listeners want to learn more about this, then they can check out our previous Genomics 101 podcast: What is the Diagnostic Odyssey? So, Nour, we know that you see children and families in their genomics journeys. Do you see adults as well?  Nour: Yes, indeed. We also see many adults who develop certain health conditions, such as cancer or certain types of heart disease, and their clinicians suspect they might be having an underlying inherited genetic cause, or it could be actually someone who is healthy themselves, but have a family history of a particular condition, and want to understand their own risk or the risk for their children and other family members. A classic example is in cancer genetics. A woman with breast cancer at a young age, or who has several family members who have also had it, she would be investigated to see if she carries a gene change that increases the risk of breast cancer and other cancers, and finding that actually would be critical for the treatment choices, and it has huge implications for her relatives.  Also, a major part of our work is in the prenatal setting, so we might see a couple during a pregnancy if the antenatal ultrasound scan, for example, shows that the baby has abnormalities. And the obstetrician might refer them to us to investigate if they have an underlying genetic reason for that. And this can help the couple and the medical team prepare for any challenges after birth and also make informed decisions about the pregnancy.   And clinical genetics is unique in that we don't see just individual patients, we often work with entire families, and if there is an inherited condition in the family, it's not unusual for several relatives across different generations to be seen by our team.  This family-wide approach helps us piece together the inheritance pattern and offer the right tests to the right people, and also ensure that everyone who might benefit from information or screening has the opportunity to access that.  Florence: So if someone has a suspected genetic condition, will they always come to you first?  Nour: Actually no, the way people come to us is changing. It used to be that you would always see clinical geneticists first, but now with genetic testing becoming more common, other clinicians like a cardiologist, a neurologist, or a paediatrician, might order a genetic test themselves.   But these tests can produce a huge amount of data, and the results are not always a simple yes or no. Sometimes the lab finds something called a variant of uncertain significance, which means a gene change that we are not certain whether it is the cause of health problems or not. And in these cases, a specialist will refer the patient to us to help put the uncertain result into the context of the patient's specific health problems, and family history, and to help also work out what it really means for them and their family.  Florence: So, you mentioned a couple of other healthcare professionals there, paediatricians and neurologists for example. Are there any other roles that you work closely with as a clinical geneticist?  Nour: Well, genetics is never a one-person job, and it's rather like a team sport, so we never work in isolation. We work in what we call a multidisciplinary team,  where clinical geneticists, genetic counsellors, genomic practitioners, scientists and other specialists, all bring our knowledge and expertise together. We also work directly with other specialists across the hospital and the NHS. Let's say if it's a genetic heart condition, a cardiologist would be a key part of this multidisciplinary team for the patient. And this 360-degree view ensures that we are giving the best possible holistic care.   Florence: And finally, before we wrap up, I'm sure lots of our listeners may have heard or even come across genetic counsellors. Could you explain how this role is different from a clinical geneticist?  Nour: So, our role as a clinical geneticist is distinct from that of a genetic counsellor, but we work side by side. Clinical geneticists, as the medical doctors on the team, we're often focused on the diagnosis, and we will perform a physical examination of the patient, looking for subtle clues. We will review their medical history, and piece together the whole medical puzzle. And based on that, we decide which genetic test is the most appropriate, and we'll have the best chance of finding an answer. A genetic counsellor is a healthcare professional with highly specialised training in both genetics and counselling. They are communication experts, they spend time helping families understand results, process the information, and think through what it means for them and their relatives. They are incredibly skilled at explaining complex genetic concepts in a way that is easy to understand, and also at providing support. They help families navigate the emotional impact of what can be life-changing news, and also discuss the implications for the wider family. And genetic counsellors are not only there after the diagnosis is made, they can also play an active role in the diagnostic process.  So in many situations, they are the ones taking the detailed family history, recognising patterns that suggest a genetic condition, and arrange the most appropriate genetic tests. They work closely with laboratory scientists and clinical geneticists to interpret the results and guide the next steps for the patient.  And a family will often see both of us as our roles complement each other.  Florence: So, we'll finish there. Thank you so much, Nour, for sharing what you do as a clinical geneticist.   If you'd like to hear more explainer episodes like this, you can find them on our website at www.genomicsengland.co.uk, or wherever you get your podcasts. Thank you for listening. 

This episode is sponsored by Invivyd, Inc.Marc Elia is a biotech investor, the Chairman of the Board at Invivyd, and a Long COVID patient who decided to challenge the system while still stuck inside it. He's not here for corporate platitudes, regulatory shoulder shrugs, or vaccine-era gaslighting. This is not a conversation about politics, but it's about power and choice and the right to receive care and treatment no matter your condition.In this episode, we cover everything from broken clinical pathways to meme coins and the eternal shame of being old enough to remember Eastern Airlines. Marc talks about what it means to build tools instead of just complaining, what Long COVID has done to his body and his patience, and why the illusion of “choice” in healthcare is a luxury most patients don't have.This conversation doesn't ask for empathy. It demands it.RELATED LINKSMarc Elia on LinkedInInvivyd Company SiteMarc's Bio at InvivydFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On this episode of the Functionally Enlightened Podcast, Sharon sits down with Piper Gibson and Bailey Williams, co-founders of Elite Gene Labs, to explore the world of functional genomics and its power in supporting those with chronic illness, environmental toxicity, and implant-related complications.Piper and Bailey share their deeply personal journeys into genomics—how neurological symptoms, autoimmune struggles, and years of unanswered questions led them to discover how genetics could guide true, personalized healing.Together, they break down:✨ How genomics goes beyond symptom management to uncover root causes✨ Detox pathways, inflammation genes, and what they reveal about healing✨ Practical strategies for diet, food sensitivities, and managing flare-ups✨ The role of functional labs alongside genetics for complex cases✨ Hope-filled transformation stories from clients with PANS/PANDAS, Lyme, mold illness, and autoimmune disordersWhether you're navigating implant illness, dysautonomia, or unexplained chronic symptoms, this episode will empower you to understand how your genetics and environment interact—and how to use that knowledge to reclaim your health.

After years of carrying the weight of lead, Shannon and Cooper find a path out from under the darkness and into the sunlight.LEAD: how this story ends is up to us is an audio docudrama series that tells the true story of one child, his mysterious lead poisoning, and his mother's unwavering fight to keep him safe. A true story written by Shannon Burkett. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.Lead was produced by Shannon Burkett. Co-produced by Jenny Maguire. Featuring Amy Acker, Tom Butler, Dennis T. Carnegie, James Carpinello, Geneva Carr, Dann Fink, Alice Kris, Adriane Lenox, Katie O'Sullivan, Greg Pirenti, Armando Riesco, Shirley Rumierk, Thom Sesma, and Lana Young. Music by Peter Salett. “Joy In Resistance” written by Abena Koomson-Davis and performed by Resistance Revival Chorus. Casting by Alaine Alldaffer and Lisa Donadio. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Urologic oncologist Dr. Peter Carroll presents the latest research on active surveillance as a preferred approach for managing low-risk prostate cancer and selected cases of intermediate-risk disease. Drawing from two decades of UCSF data, he explains how long-term outcomes support the safety and effectiveness of delaying treatment for carefully monitored patients. Carroll emphasizes that surveillance decisions should be guided by MRI imaging, PSA density, cancer volume, histologic subtype, and genomic testing. He notes that while many men experience gradual changes over time, only a small percentage require immediate treatment. Carroll also discusses innovations such as AI-assisted pathology and risk profiling to reduce unnecessary procedures. His data-driven approach offers patients a personalized path that preserves quality of life without compromising outcomes. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40801]

Urologic oncologist Dr. Peter Carroll presents the latest research on active surveillance as a preferred approach for managing low-risk prostate cancer and selected cases of intermediate-risk disease. Drawing from two decades of UCSF data, he explains how long-term outcomes support the safety and effectiveness of delaying treatment for carefully monitored patients. Carroll emphasizes that surveillance decisions should be guided by MRI imaging, PSA density, cancer volume, histologic subtype, and genomic testing. He notes that while many men experience gradual changes over time, only a small percentage require immediate treatment. Carroll also discusses innovations such as AI-assisted pathology and risk profiling to reduce unnecessary procedures. His data-driven approach offers patients a personalized path that preserves quality of life without compromising outcomes. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40801]

Urologic oncologist Dr. Peter Carroll presents the latest research on active surveillance as a preferred approach for managing low-risk prostate cancer and selected cases of intermediate-risk disease. Drawing from two decades of UCSF data, he explains how long-term outcomes support the safety and effectiveness of delaying treatment for carefully monitored patients. Carroll emphasizes that surveillance decisions should be guided by MRI imaging, PSA density, cancer volume, histologic subtype, and genomic testing. He notes that while many men experience gradual changes over time, only a small percentage require immediate treatment. Carroll also discusses innovations such as AI-assisted pathology and risk profiling to reduce unnecessary procedures. His data-driven approach offers patients a personalized path that preserves quality of life without compromising outcomes. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40801]

ReferencesFront. Immunol 2020. 03 February Sec. T Cell BiologyGeneReviews®[ [updated 2024 Feb 1] Seattle (WA): University of Washington, Seattle;Open Biol. 2020 Dec 16;10(12):200295.Cell. 1989 May 19;57(4):645-58. Journal of Genetics and Genomics 2020.V. 47, Issue 1, 20 January Pages 17-26Plant/Paige. 1975 "In the Light". on Physical Graffitihttps://music.youtube.com/watch?v=pNo1nS_JV5k&si=aD1HwJTkegLhjRCRLodge, J. 1969. "Candle of LIfe" To Our Children's Children." lp. Moody Blueshttps://music.youtube.com/watch?v=BVkIUY2s-7o&si=F5GrPlT-hklKTTGqDobson .B. 1961. "Morning Dew" Grateful Dead Europe 72'. lphttps://music.youtube.com/watch?v=jYR3sBmomgQ&si=vLBLIStvXYBFoaJc

The deficits from the lead poisoning continue to intensify, Shannon channels her anger and grief into holding the people who hurt her son responsible.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.EP4 features Eboni Booth, Sasha Eden, Kevin Kane, April Matthis, Alysia Reiner, and Mandy Siegfried. Casting by Alaine Alldaffer and Lisa Donadio. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome back to another episode of Brands and Barbed Wire.   This week we continue our Future of Beef series where we interview Nick Jorgensen with Jorgensen Land and Cattle.  We've interviewed the Jorgensen family before here on Brands and Barbed Wire which is an incredible episode if you haven't listened.  It's about the family's history in the Angus business and details the famous FBI raid on the ranch.   This episode from the Future of Beef focuses more on the technology they utilize on their ranch in SD.   We hope you enjoy the show and more information on the Future of Beef visit www.thefutureofbeef.com. Thanks to our sponsors Allied Genetic Resources www.alliedgeneticresources.com, The Grant Company at www.grantcompany.net, B.R. Cutrer Ranch www.brcutrer.com, Jorgensen Land and Cattle www.jorgensenfarms.com

In this episode of the AgCulture Podcast, Eric McNeilly, International Premier Account Manager at Alta Genetics, shares insights from his 49-year career in the global dairy industry. From managing herds of over 20,000 cows to restructuring troubled farms across six continents, Eric explains the systems, cultural dynamics, and technologies driving efficient dairy operations. Learn practical management strategies and how to future-proof your dairy business. Listen now on all major platforms!Meet the guest: Eric McNeilly has nearly five decades of experience in the dairy industry, including managing herds of over 200,000 cows and consulting across 22 countries. With deep expertise in labor efficiency, dairy systems, and genetics, he now serves as International Premier Account Manager at Alta Genetics.What you will learn: (00:00) Introduction(05:11) Managing large herds(14:11) Cross-cultural leadership(15:31) Farm restructuring systems(24:15) Genomics in breeding(28:23) Technology in dairy(37:01) Closing thoughtsDiscover the world of agriculture with the "Ag Culture Podcast".  This podcast will be a gateway for those passionate about agriculture to explore its global perspectives and innovative practices.Join Paul as he shares his experiences in the agricultural industry, his travels and encounters with important figures around the world.Available on YouTube, Spotify and Apple Podcasts.Subscribe at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.agculturepodcast.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and keep an eye out for future episodes, bringing insights and stories from the vibrant world of agriculture.

HIV, superbugs, and standards—oh my! In this episode of Absolute Gene-ius, we explore the frontier of infectious disease research with Dr. Jesús Mingorance, researcher at Hospital Universitario La Paz in Madrid. His research is translational and uses digital PCR, qPCR, sequencing, and more.Dr. Mingorance walks us through his application of ultra-sensitive PCR methods to track HIV-2 viral loads—particularly in challenging cases where standard assays fall short. He shares how digital PCR enabled detection in samples where conventional tests failed, and how it's becoming essential for assay calibration and microbial quantification. He also dives into the endemic challenges of carbapenem-resistant Klebsiella pneumoniae in hospitals, revealing the clinical and epidemiological importance of quantifying pathogen load within the microbiome.In the career corner, Dr. Mingorance recounts his unconventional journey—from humanities student to biologist inspired by a single sentence about DNA. With humor and honesty, he reflects on the patience needed in science, the value of good questions, and the importance of mentoring new scientists. “Biology is beautiful,” he reminds us. We agree.Visit the Absolute Gene-ius pageto learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System. 

The effects of the neurotoxin are taking their toll on Cooper as Shannon desperately tries to navigate the severity of their new reality.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.E43 features Jenny Maguire, JD Mollison, Laith Nakli, Deirdre O'Connell, Carolyn Baeumler, Zach Shaffer, and Monique Woodley. Casting by Alaine Alldaffer and Lisa Donadio. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

As the lead wreaks havoc on Cooper's development, Shannon searches for answers. Desperate to get a handle on what was happening to her son, she grabs onto a lifeboat - nursing school. Andy tries to piece together the past to make sense of the present.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper BurkettEP2 features Keith Nobbs and Frank Wood. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes. Casting by Alaine Alldaffer and Lisa Donadio.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The first complete draft of the human genome was published back in 2003. Since then, researchers have worked both to improve the accuracy of human genetic data, and to expand its diversity, looking at the genetics of people from many different backgrounds. Three genetics experts join Host Ira Flatow to talk about a recent close examination of the genomes of 65 individuals from around the world, and how it may help researchers get a better understanding of genomic functioning and diversity.Guests:Dr. Christine Beck is an associate professor of genetics and genome sciences in the University of Connecticut Health Center and the Jackson Laboratory.Dr. Glennis Logsdon is an assistant professor of genetics and a core member of the Epigenetics Institute at the University of Pennsylvania.Dr. Adam Philippy is a Senior Investigator in the Center for Genomics and Data Science Research at the National Human Genome Research Institute at the NIH.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

A mysterious dust fills a young family's apartment. The truth begins to unravel when the mother gets a call from the pediatrician - the monster deep within the walls has been unleashed. LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett. EP1 features Zak Orth, Jenny Maguire, Daphne Gaines, and Micheal Gaston. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes. Casting by Alaine Alldaffer and Lisa Donadio.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.